Eye doctors fighting Genentech decision

The California Academy of Eye Physicians and Surgeons has issued a call for South San Francisco’s Genentech Inc. (DNA) to reverse its decision to halt sales of its drug Avastin to compounding pharmacies effective November 30, 2007.

The group is asking the California Medical Association and possibly the American Medical Association to take a stand on the issue as well.

Opthalmologists have been using Avastin, a drug currently only approved for cancer, to treat age-related macular degeneration, a common eye disease. Because only a small portion of a standard dose is needed for eye treatment, eye doctors have generally purchased the drug from compounding pharmacies, which repackage it in smaller doses.

Genentech, however, also sells a similar but much more expensive drug, Lucentis, which according to information provided by the physicians sells for approximately $2,000 a dose versus approximately $40 a dose for Avastin.

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

‘Mad Mob’ aims to influence SF City Hall on mental health policies

They are fed up with City Hall telling those who need the services what’s best for them

Police efforts to stem 49ers revelry in Mission District spark backlash

SFPD preparing for potential bonfires, vandalism on Super Bowl Sunday

Calendar of Events: San Francisco celebrates the Year of the Rat

JAN. 25 Choy Sun Doe Day: The San Francisco Chinese Chamber of… Continue reading

BART study: Ending paper tickets would ‘disproportionately’ impact low-income riders, people of color

When BART eventually eliminates its magnetic-stripe paper tickets from use, it will… Continue reading

Second case of respiratory coronavirus confirmed in U.S.

The woman, who is in her 60s, remained hospitalized Friday and her condition had been stabilized

Most Read